Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 41 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Adacel® Vaccine Administered to Persons 10 Years of Age

NCT01311557
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
10 Years to 11 Years
Enrollment
1,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
34
States / cities
Chandler, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 31 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Entolimod, an Adjuvant for Vaccine Augmentation

NCT03063736
Conditions
Substance Use Disorders
Interventions
Entolimod, Td Vaccine
Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pertussis, Tetanus, Diphtheria
Interventions
ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
1,564 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
19
States / cities
Chandler, Arizona • Phoenix, Arizona • Cypress, California + 15 more
Conditions
Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Interventions
Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 7 Years
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
26
States / cities
Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more
Completed Phase 1 Interventional Accepts healthy volunteers

Pertussis Vaccine in Healthy Pregnant Women

NCT00707148
Conditions
Diphtheria, Pertussis, Tetanus
Interventions
Placebo, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
4
States / cities
Durham, North Carolina • Houston, Texas • Seattle, Washington
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Conditions
Diphtheria, Tetanus, Pertussis, Polio, Haemophilus Infection
Interventions
Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
19
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Oakland, California + 16 more
Completed Phase 1 Interventional Results available

IDH1 Peptide Vaccine for Recurrent Grade II Glioma

NCT02193347
Conditions
Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor, Cancer of the Brain
Interventions
PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid (Td), Temozolomide
Biological · Drug
Lead sponsor
Katy Peters, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Diphtheria, Tetanus
Interventions
Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Years to 60 Years
Enrollment
3,651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
2
States / cities
Oakland, California • Pittsburgh, Pennsylvania
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Conditions
Acellular Pertussis, Diphtheria, Tetanus
Interventions
Fluarix®, Boostrix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years and older
Enrollment
1,726 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
12
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 8 more
Conditions
HIV Infections
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed, Bacteriophage phi X 174, Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 8 more
Conditions
Pertussis, Tetanus, Diphtheria
Interventions
ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
11 Years to 18 Years
Enrollment
647 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
10
States / cities
Annapolis, Maryland • Baltimore, Maryland • Frederick, Maryland + 6 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

NCT00347958
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 69 Years
Enrollment
545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
4
States / cities
Jonesboro, Arkansas • Bossier City, Louisiana • University Heights, Ohio + 1 more
Conditions
Acellular Pertussis, Tetanus, Diphtheria
Interventions
Boostrix®, Menactra™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years
Enrollment
1,344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
24
States / cities
Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 18 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors

NCT05662852
Conditions
Tetanus, Diphtheria and Acellular Pertussis Vaccination
Interventions
Tdap
Biological
Lead sponsor
ABO Holdings, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Glassboro, New Jersey
Conditions
Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian High Grade Serous Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Primary Peritoneal High Grade Serous Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Mixed Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Leukapheresis, Magnetic Resonance Imaging, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Placebo Administration, Tetanus and Diphtheria Toxoids Adsorbed
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota